{
    "body": "Orteronel was developed for treatment of which cancer?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24799061", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24418642", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25537627", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25701170", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25624429", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25264242", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21978946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26150028", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24100689"
    ], 
    "ideal_answer": [
        "Orteronel was developed for treatment of castration-resistant prostate cancer."
    ], 
    "exact_answer": [
        "castration-resistant prostate cancer"
    ], 
    "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:162"
    ], 
    "type": "factoid", 
    "id": "56c1f01def6e394741000045", 
    "snippets": [
        {
            "offsetInBeginSection": 225, 
            "offsetInEndSection": 395, 
            "text": "Pooled-analysis was also performed, to assess the effectiveness of agents targeting the androgen axis via identical mechanisms of action (abiraterone acetate, orteronel).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150028", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 953, 
            "offsetInEndSection": 1087, 
            "text": "The experimental interventions tested in these studies were enzalutamide, ipilimumab, abiraterone acetate, orteronel and cabazitaxel. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150028", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1540, 
            "offsetInEndSection": 1879, 
            "text": " Pooled analysis of androgen synthesis inhibitors orteronel and abiraterone resulted in significantly increased overall and progression-free survival for anti-androgen agents, compared to placebo (hazard ratio for death: 0.76, 95% CI 0.67 to 0.87, P<0.0001; hazard ratio for radiographic progression: 0.7, 95% CI 0.63 to 0.77, P<0.00001). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150028", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2416, 
            "offsetInEndSection": 2541, 
            "text": "Agents targeting the androgen axis (enzalutamide, abiraterone, orteronel) significantly prolonged rPFS, compared to placebo. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150028", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 197, 
            "text": "Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 320, 
            "text": "BACKGROUND: Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2578, 
            "offsetInEndSection": 2793, 
            "text": "NTERPRETATION: In chemotherapy-naive patients with metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel plus prednisone versus placebo plus prednisone.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2986, 
            "offsetInEndSection": 3123, 
            "text": "On the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 265, 
            "text": "Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25624429", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 111, 
            "offsetInEndSection": 246, 
            "text": "This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25624429", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1690, 
            "offsetInEndSection": 1780, 
            "text": "Longer rPFS and a higher PSA50 rate with orteronel-prednisone indicate antitumor activity.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25624429", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 106, 
            "text": "A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25537627", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 97, 
            "offsetInEndSection": 305, 
            "text": "We evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer (CRPC).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25537627", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1553, 
            "offsetInEndSection": 1642, 
            "text": "CONCLUSIONS: Orteronel at doses up to 400 mg BID was tolerable in Japanese CRPC patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25537627", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 47, 
            "text": "Orteronel for the treatment of prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 128, 
            "text": "Orteronel (also known as TAK-700) is a novel hormonal therapy that is currently in testing for the treatment of prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 170, 
            "text": "Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25264242", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 749, 
            "offsetInEndSection": 1043, 
            "text": "Early reports of clinical studies demonstrate that orteronel treatment leads to reduced prostate-specific antigen levels, a marker of prostate cancer tumor burden, and more complete suppression of androgen synthesis than conventional androgen deprivation therapies that act in the testes alone.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 175, 
            "text": "Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21978946", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 790, 
            "offsetInEndSection": 993, 
            "text": "Therefore, (+)-3c (termed orteronel [TAK-700]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21978946", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 307, 
            "offsetInEndSection": 413, 
            "text": "We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 171, 
            "text": "Orteronel is a nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25264242", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 148, 
            "text": "Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24418642", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 2986, 
            "offsetInEndSection": 3232, 
            "text": "On the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25701170", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 685, 
            "offsetInEndSection": 1043, 
            "text": "New androgen biosynthesis inhibitors have been developed, such as orteronel (TAK-700), but also new antiandrogens (enzalutamide, ARN-509, ODM-201) or even agents with a dual mechanism of action (galeterone). In this review the development of new hormonal therapies following the arrival of abiraterone for the treatment of prostate cancer will be summarized.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24100689", 
            "endSection": "abstract"
        }
    ]
}